RhumbLine Advisers’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-15,258
Closed -$352K – 3054
2020
Q4
$352K Buy
15,258
+1,050
+7% +$13.3K ﹤0.01% 2598
2020
Q3
$145K Sell
14,208
-808
-5% -$10.8K ﹤0.01% 2783
2020
Q2
$224K Buy
+15,016
New +$231K ﹤0.01% 2721

RhumbLine Advisers's PRVL Position: Q1 2021 in Review

RhumbLine Advisers sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 15,258 shares — an estimated $352K sold.

RhumbLine Advisers first reported a position in PRVL in Q2 2020 and held it in 3 quarters. The position peaked at $352K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • RhumbLine Advisers reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 15,258 Prevail Therapeutics shares in Q1 2021, an estimated $352K.
  • RhumbLine Advisers first reported a position in Prevail Therapeutics in Q2 2020 and held it in 3 quarters.
  • RhumbLine Advisers's Prevail Therapeutics position peaked at $352K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.

Based on RhumbLine Advisers's 13F filing for Q1 2021, filed 6 May 2021.